InMed Pharmaceuticals (INM) Research & Development (2019 - 2026)

InMed Pharmaceuticals has reported Research & Development for 8 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 140.41% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 6.17% YoY), and the FY2025 full-year result was $2.9 million, down 11.3% from the prior year.
• Research & Development for Q1 2026 stood at $1.0 million, up from $630636.0 in the prior quarter.
• The five-year high for Research & Development was $1.8 million in Q1 2022, with the low at $425370.0 in Q1 2025.
• Historically, Research & Development has averaged $886435.7 across 5 years, with a median of $700145.0 in 2024.
• Annual changes were most pronounced in 2022 — Research & Development sank 66.44% — and 2026, when it surged 140.41%.
• InMed Pharmaceuticals' Research & Development stood at $851356.0 in 2022, then slipped by 28.37% to $609791.0 in 2023, then surged by 46.8% to $895176.0 in 2024, then declined by 29.55% to $630636.0 in 2025, then soared by 62.16% to $1.0 million in 2026.
• The last three Research & Development figures came in at $1.0 million (Q1 2026), $630636.0 (Q4 2025), and $581612.0 (Q3 2025), per Business Quant data.